BioParadox: Cell Therapy for Cardiovascular Disease at the Point of Care

article image
ARTICLE SUMMARY:

BioParadox is developing a new therapy paradigm for cardiovascular and vascular disease, beginning with patients suffering from claudication. The company has developed a patented formulation of platelet-rich-plasma (PRP) and a device for producing it from the patient’s own blood within minutes at the point of care.

BioParadox Inc. is developing new therapies for unmet needs in vascular and cardiovascular disease, beginning with patients suffering from intermittent claudication. The company has developed a patented formulation of PRP and a disposable device for producing it from a patient’s own blood within minutes at the point of care.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.


Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite

Questions?

We're here to help! Please contact us at: